ABVX
Abivax SA
$122.74
-1.53%
2026-05-08
About Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Key Fundamentals
Forward P/E
-44.08
EPS (TTM)
$-5.66
ROE
-135.6%
Revenue Growth (YoY)
-55.4%
Profit Margin
0.0%
Debt/Equity
7.05
Price/Book
18.49
Beta
-0.19
Market Cap
$9.96B
Avg Volume (10D)
916K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$133.42
60D Low
$100.15
Avg Volume
901K
Latest Close
$122.74
Get breakout alerts for ABVX
Sign up for Breakout Scanner to receive daily notifications when ABVX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Abivax SA (ABVX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ABVX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ABVX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.